Amgen (AMGN) Getting Somewhat Negative News Coverage, Study Shows

Share on StockTwits

News articles about Amgen (NASDAQ:AMGN) have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Amgen earned a media sentiment score of -1.00 on their scale. InfoTrie also assigned headlines about the medical research company an news buzz score of 6 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock’s share price in the next several days.

Here are some of the media stories that may have effected Amgen’s ranking:

Several equities research analysts have weighed in on the stock. Oppenheimer reaffirmed a “buy” rating and issued a $224.00 price target on shares of Amgen in a research note on Tuesday, October 2nd. Jefferies Financial Group reissued a “buy” rating and set a $220.00 target price on shares of Amgen in a research report on Friday, August 24th. Morgan Stanley boosted their target price on shares of Amgen from $210.00 to $212.00 and gave the stock an “overweight” rating in a research report on Thursday, October 11th. Leerink Swann set a $209.00 target price on shares of Amgen and gave the stock a “hold” rating in a research report on Monday, September 17th. Finally, Cantor Fitzgerald reissued a “hold” rating and set a $223.00 target price on shares of Amgen in a research report on Wednesday, October 31st. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have given a buy rating to the company’s stock. Amgen currently has a consensus rating of “Hold” and an average price target of $204.55.

Amgen stock traded down $2.86 during midday trading on Friday, hitting $193.16. 2,339,671 shares of the stock were exchanged, compared to its average volume of 3,266,681. Amgen has a 52-week low of $163.31 and a 52-week high of $210.19. The stock has a market cap of $125.93 billion, a PE ratio of 15.35, a price-to-earnings-growth ratio of 2.05 and a beta of 1.37. The company has a debt-to-equity ratio of 2.05, a quick ratio of 2.84 and a current ratio of 3.08.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, October 30th. The medical research company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.45 by $0.24. Amgen had a net margin of 9.44% and a return on equity of 54.14%. The business had revenue of $5.90 billion for the quarter, compared to analysts’ expectations of $5.78 billion. During the same period in the previous year, the company earned $3.27 earnings per share. The firm’s revenue for the quarter was up 2.3% compared to the same quarter last year. As a group, analysts predict that Amgen will post 14.24 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 7th. Investors of record on Friday, November 16th will be issued a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a yield of 2.73%. The ex-dividend date of this dividend is Thursday, November 15th. Amgen’s dividend payout ratio (DPR) is presently 41.97%.

WARNING: “Amgen (AMGN) Getting Somewhat Negative News Coverage, Study Shows” was first posted by Equities Focus and is owned by of Equities Focus. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Recommended Story: What is a Stop Order?

Insider Buying and Selling by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with's FREE daily email newsletter.

Leave a Reply